Ironwood Pharmaceuticals Inc
IRWD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001446847
No open-market purchases or sales by Ironwood Pharmaceuticals Inc insiders were filed in the last 90 days; 212 institutions reported holding it in 13F filings for Q2 2026, worth $675.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $806.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −12 vs. previous quarter
- 212
- 13F valueReported value at the end of Q2 2026
- $675.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $296.2M
- −15.7% year over year
- Net income, FY2025
- $24.0M
- +2,629.2% year over year
- Free cash flow, FY2025
- $127.0M
- +22.8% year over year
- Revenue, Q3 FY2026
- $133.0M
- +9.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 14.9M
- Shares sold short
- Change
- −1.03M
- −6.5% vs. previous
- Days to cover
- 9.84
- At average daily volume
Superinvestors holding IRWD, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding IRWD at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Ironwood Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 (view filing)4:32 PM ET | Jul 7 | 2 days | Silver RonaldPFO & PAO | SSaleClass A Common Stock | −127.9K | $4.52 | −$578.1K | −29.0%313.7K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | McHugh JulieDirector | SSaleClass A Common Stock | −21.6K | $3.73 | −$80.5K | −7.9%250.7K after | 10b5-1 |
| Mar 17, 2026 (view filing) | Mar 17 | Same day | Denner Alexander JDirector | SSaleClass A Common Stock | −6.73M | $3.05 | −$20.5M | −42.3%9.19M after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Martini Gregory S.Chief Financial Officer | SSaleClass A Common Stock | −21.9K | $3.73 | −$81.9K | −12.0%160.6K after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | John MinardoChief Legal Officer | SSaleClass A Common Stock | −36.5K | $3.73 | −$136.2K | −9.1%363.9K after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSaleClass A Common Stock | −15.6K | $3.81 | −$59.3K | −2.8%538.4K after | |
| Feb 25, 2026 (view filing) | Feb 24 | 1 day | Shetzline MichaelSVP, CMO, Head-Res&Drug | SSale | +17.0K | $3.66 | +$62.3K | +3.4%521.4K after | |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Gaskins Tammi LChief Commercial Officer | SSaleClass A Common Stock | −21.5K | $3.73 | −$80.3K | −9.1%213.7K after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | MCCOURT Thomas AChief Executive Officer | SSaleClass A Common Stock | −198.3K | $3.73 | −$739.9K | −11.8%1.49M after | 2 lots |
| Feb 25, 2026 (view filing) | Feb 23-24 | 2 days | Silver RonaldPrincipal Accounting Officer | SSaleClass A Common Stock | −24.2K | $3.73 | −$90.2K | −8.7%252.6K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 212 holdersThe largest institutional positions in Ironwood Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 17,788,557 | $74.9M | 0.00% | +4,425,627+33.1% | Added |
| Armistice Capital, LLC | 13,932,000 | $58.7M | 1.62% | −1,096,000−7.3% | Reduced |
| Sarissa Capital Management LP | 9,188,635 | $38.7M | 21.75% | 00.0% | Unchanged |
| State Street Corp | 8,809,601 | $37.1M | 0.00% | +1,352,657+18.1% | Added |
| Bank of America Corp | 8,683,803 | $36.6M | 0.00% | +8960.0% | Added |
| Renaissance Technologies LLC | 7,993,226 | $33.7M | 0.05% | −67,847−0.8% | Reduced |
| Vanguard Capital Management LLC | 6,608,508 | $27.8M | 0.00% | +511,054+8.4% | Added |
| AQR Capital Management LLC | 6,465,921 | $27.2M | 0.01% | −1,069,159−14.2% | Reduced |
| Acadian Asset Management LLC | 5,853,331 | $24.6M | 0.03% | −723,941−11.0% | Reduced |
| Vanguard Portfolio Management LLC | 5,513,355 | $23.2M | 0.00% | −1,168,682−17.5% | Reduced |
Holders of 5% or more of IRWD
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Ironwood Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 13G/A | 9.94%16.1M shares | – | Aug 15, 20251 filing | Aug 15, 2025 | SEC |
| Armistice Capital, LLC | 13G/A | 8.43%13.9M shares | −0.79 ppfrom 9.22% | Nov 14, 20246 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 8.10%13.4M shares | +1.00 ppfrom 7.10% | Oct 23, 20244 filings | Jul 28, 2026 | SEC |
| Sarissa Capital Management LP | 13D/A | 5.80%9.44M shares | – | Mar 1, 20212 filings | Mar 19, 2026 | SEC |